Its inhaled insulin will succeed where Big Pharma failed, MannKind says
Will a small California biotech get the last laugh on Eli Lilly and Co., Pfizer, Novo Nordisk and the rest of Big Pharma? Or will it just be the latest to learn a tough lesson: that new diabetes drugs that seem like breakthroughs on paper often face a bumpy road with patients, doctors and health insurers? For more than a decade, MannKind Corp.
Join the discussion below, or Read more at The Indianapolis Star.
#1 Jun 1, 2009
According Al Mann, Chairman and CEO of Mannkind Corp, a billionaire with an incredible track record, Afresa will be a multi-billion dollar revenue drug at a minimum. Increasingly, endocrinologists are understanding that insulin is the ideal treatment of type 2 diabetes, but, unfortunately, present day fast acting insulins aren't fast enough. Afresa is the solution to this problem. Early stage type 2 patients will take inhalable insulin. And Afresa will be covered by healtrh insurance companies because the impliations are improved overall health, thus reduced costs.
Add your comments below
|If Approved -- FDA Drug Labeling Could Decide U... (Feb '10)||Feb '10||Reen||1|
Find what you want!
Search MannKind Forum Now
Copyright © 2016 Topix LLC